The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Zefei Jiang
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Romualdo Barroso-Sousa
Consulting or Advisory Role - AstraZeneca; AstraZeneca/Daiichi Sankyo; AstraZeneca/Merck; Libbs; Lilly; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Libbs; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca/Daiichi Sankyo
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; AstraZeneca/Daiichi Sankyo; MSD; Novartis
Other Relationship - RD EDUCACAO MEDICA
 
Yeon Hee Park
Honoraria - AstraZeneca; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Inocras (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Gilad
 
Mothaffar Rimawi
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Novartis; Pfizer; Sermonix Pharmaceuticals
Research Funding - Greenwich LifeSciences (Inst)
 
Cristina Saura Manich
Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Exeter Pharmaceuticals; Pfizer; Phillips Health Works; Pierre Fabre; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; F. Hoffmann LaRoche; Gilead Sciences; Lilly; MediTech; Menarini; Menarini; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Debiopharm Group (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Janssen-Cilag SA (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merck Health KGAA, Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); SERVIER (Inst); Spanish Association Against Cancer Scientific Foundation and Cancer Research UK (Inst); Taiho Pharma USA Inc, (Inst)
Expert Testimony - AX`s consulting SARL; Boehringer Ingelheim; Bristol-Myers Squibb/Sanofi; Genentech; InnoUp; Merck Sharp and Dohme Spain; Novartis; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Puma Biotechnology; Roche; Seagen
 
Andreas Schneeweiss
Honoraria - Amgen; AstraZeneca; Aurikamed; ClinSol; coma UroGyn; Connectmedica; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; I-MED; if-kongress; iOMEDICO; Lilly; MCI Deutschland; MSD; Novartis; Onkowissen; Pfizer; Promedicis; Roche; Seagen; Streamedup!
Research Funding - Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Pfizer; Roche
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Devicor Medical Products; Eisai; Exact Sciences; Kyowa Kirin; Lilly; MSD; Nippon Kayaku; Pfizer; Shimadzu; Sysmex; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Bertis; Daiichi Sankyo; Kansai Medical; Lilly; Terumo
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer
Research Funding - AFI technology; AstraZeneca; Daiichi Sankyo; Eisai; GL Sciences; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Lilly (Inst); Lux Biosciences; Pfizer; Sanwa Shurui; Yakult Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Other Relationship - Asian Journal of Surgery; Asian Journal of Surgery; Breast Cancer research and Treatment; British Journal of Cancer; Cancer Science; Japanese Breast Cancer Society; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research; Scientific Reports
 
Yasemin Kemal
No Relationships to Disclose
 
Mukesh Chaudhari
No Relationships to Disclose
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Kyowa Hakko Kirin; Lilly; MSD; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Ono Yakuhin (Inst); Pfizer (Inst); Seagen (Inst)
 
Monica Casalnuovo
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Knight Pharmaceuticals
Research Funding - AstraZeneca; Daichii Sanchio; Lilly Medical; Merus
Travel, Accommodations, Expenses - Raffo
 
Michael Danso
Honoraria - Amgen
Consulting or Advisory Role - Agendia; AstraZeneca; bioTheranostics; Genentech; Gilead Sciences; Immunomedics; Lilly; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen; Stemline Therapeutics
 
Jie Liu
Employment - AstraZeneca
 
Jagdish Shetty
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Daiichi Sankyo
 
Pia Herbolsheimer
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Sibylle Loibl
Employment - Bethanien Krankenhaus
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini Group (Inst); MSD Oncology (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Speakers' Bureau - Agendia (Inst); AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Medscape (Inst); Menarini Group (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Streamedup! (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Greenwich LifeSciences (Inst); Menarini Group (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); MSD (Inst); Roche (Inst)